Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

ate Phase 2 trials of BSI-201, reflecting the breadth of tumor types that could be sensitive to the drug."

The company is currently conducting a Phase 2 trial of BSI-201 in triple- negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme (GBM), the most common brain cancer in adults. An additional trial in uterine cancer is expected to begin enrollment in the coming weeks. The company also plans to present data from its Phase 1 trials of BSI-201 in solid tumors at the American Society of Clinical Oncology Annual Meeting that begins later this month in Chicago.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., Nov. 25 ERT (Nasdaq: ...ey, the Company,s President and CEO, and Keith Sch...FO, are scheduled to present at the 21st Annual Pi...on December 1, 2009 in New York City, New York. ,... by visiting the Company,s corporate website at h...
(Date:11/25/2009)..., Fla., Nov. 25 For many...pecially the 27 million living with untreated hea..., says audiologist Cindy Beyer. ,, Dr. Beyer, s... of America,s largest hearing care and hearing ai...ss to stress, frustration, and social isolation, "...
(Date:11/25/2009)...China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- Chin...r "the Company") (Nasdaq: CSKI ), a,leading fully...producing,over-the-counter drugs in the People,s R... Company recently passed the Chinese National Inst...ical Products ("ICPBP") examination,for two of its...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 1NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 2NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 3Cooperation Between Faith Based Organizations and UNFPA Critical to Maternal Health Say Groups 53875 1Cooperation Between Faith Based Organizations and UNFPA Critical to Maternal Health Say Groups 53875 2deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results 13422 1deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results 13422 2
...tients, LOUISVILLE, Ky., Sept. 29 Potentia Pharm... developing medicines for the treatment,of age-rel...at the,Company,s leading drug candidate, POT-4, ha... I study. POT-4 is a complement inhibitor, which s...ould otherwise lead to local,inflammation, tissue ...
...o improve healthcare,system in the Democratic Repu...n Global,Initiative recognized BD (Becton, Dickins...dical technology company, for its commitment to th...ne system monitoring and,healthcare worker safety ...search Center in the Democratic Republic of the Co...
Other Medicine Technology:Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 3
(Date:11/29/2009)...isorder boosts urine production, experts say , ...le who wake up during the night to urinate shouldn... apnea, a breathing-related sleep disorder, could ...time urination, or nocturia, is comparable to loud...a disorder in which soft tissue in the throat bloc...
(Date:11/28/2009)...PRNewswire/ -- Get ready for advanced visualiza...tine when Siemens introduces syngo. via(1...ting of the Radiological Society of North America ... Place (Booth #825, East Building/Lakeside Center,...mens, new imaging software for multimodality readi...
(Date:11/27/2009).... 27 GSI Group Inc. (Pin...cision technology products and semiconductor syste...Company,s shareholders has been scheduled for Frid...meeting will be announced in due course. As previ...n notice from Stephen Bershad, a holder of greater...
(Date:11/27/2009)...7 The Gymboree Corporati...CFO/COO, will present at the NASDAQ OMX 23rd Inves...tel in London, England, on Wednesday, December 2, ... broadcast of The Gymboree Corporation,s presentat...ee.com, click on "Our Company" at the bottom of th...
(Date:11/27/2009)...re Holdings has announced that it has become a nat...the largest nonprofit organizations dedicated to a... Delray Beach, FL (Vocus) N...: XCHO), a company specializing in the marketing a...ucts, has announced today that is has become a nat...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4
...e International SPA,Association Monday issued a re... by a major outside research firm, citing a number...ith the research. This recall includes,all informa...ropean Consumer Report, done in partnership with I...
...d restriction, weigh-ins when aided by trained sup...tensive support from a heart failure nurse and a m... heart failure patients will comply with crucial n...ducation and counseling by heart failure nurses on...
... reduced risk by as much as 60%, researchers say ,...e-counter pain medicines called non-steroidal anti...f Parkinson,s disease, according to a study by res...they,d taken aspirin or non-aspirin NSAIDs (such a...
... transplantation who also suffer from other medica...ntation. These comorbid problems, which include c...monary disease (COPD), connective tissue disease a...published in the November issue of Liver Transplan...
...sthmus Group, Inc.,("TIGroup"), (OTC Bulletin Boar... healthcare industry, announced the acquisition of...ion LLC ("RHA"). Based in Oklahoma City,RHA owns a..., "TIGroup is building,a portfolio of interests in...
...ort for Contributions to the Environment and ...IS, Nov. 5 In a new online video and podcast,rele...ed scientists,economists and thought leaders discu... the lives of third-world farm,families and commun...
Other Medicine News:Health News:ISPA Issues Immediate Recall of 2007 Global Consumer Studies 2Health News:Nurse-Led Intervention Boosts Cardiac Rehab: Study 2Health News:NSAIDs Protect Against Parkinson's Disease 2Health News:Predicting survival after liver transplantation 2Health News:TIGroup Acquires Controlling Interest in Healthcare Services Provider 2Health News:TIGroup Acquires Controlling Interest in Healthcare Services Provider 3Health News:Fourteen Global Experts Comment on the Safety and Use of Genetically Modified Food Crops 2Health News:Fourteen Global Experts Comment on the Safety and Use of Genetically Modified Food Crops 3Health News:Fourteen Global Experts Comment on the Safety and Use of Genetically Modified Food Crops 4
7121B Sony Medical Monitor
Panoview Plus Arthroscopes
A1 Single-Chip Camera
Arthroscope
Medicine Products: